Stock Movers Goldman Higher on Earnings; Apple Tariff Relieve; Pfizer Drug Pivot
4 snips
Apr 14, 2025 Goldman Sachs reports strong earnings, boosting its shares and announcing a massive share buyback. Apple benefits from tariff exemptions, with analysts bullish on its stock. Meanwhile, Pfizer faces setbacks by abandoning its obesity pill due to health risks, shifting focus to early-stage treatments. In chip news, Intel sees a rise as US tariffs on tech pause, and it approaches a deal to divest a stake in its chips unit.
AI Snips
Chapters
Transcript
Episode notes
Goldman Sachs Performance
- Goldman Sachs saw a 27% rise in equities trading revenue in Q1 2024, reaching nearly $4.2 billion.
- They also announced a substantial $40 billion share buyback program.
Apple and Tech Stocks Rise
- Apple's stock rose by up to 5% due to news of tariff exemptions on certain tech products.
- This positive impact extended to other tech companies like Dell, HP, and chip manufacturers like NVIDIA.
Pfizer's Setback
- Pfizer discontinued its obesity pill, danuglipron, after a potential liver injury in a trial patient.
- This benefits competitors like Novo Nordisk and Eli Lilly, whose shares rose.